Tema Etfs LLC Reduces Stake in Insmed, Inc. $INSM

Tema Etfs LLC cut its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 48.1% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 4,765 shares of the biopharmaceutical company’s stock after selling 4,416 shares during the quarter. Tema Etfs LLC’s holdings in Insmed were worth $480,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Amundi boosted its holdings in Insmed by 21,194.4% in the second quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock valued at $1,130,000 after acquiring an additional 11,445 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Insmed by 59.9% in the 2nd quarter. Marshall Wace LLP now owns 1,113,361 shares of the biopharmaceutical company’s stock worth $112,049,000 after purchasing an additional 417,124 shares during the period. Baird Financial Group Inc. bought a new stake in shares of Insmed during the 2nd quarter valued at about $2,589,000. First Trust Advisors LP increased its position in shares of Insmed by 80.8% during the second quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock valued at $4,770,000 after buying an additional 21,176 shares during the period. Finally, Guggenheim Capital LLC raised its stake in Insmed by 16.8% in the second quarter. Guggenheim Capital LLC now owns 41,391 shares of the biopharmaceutical company’s stock worth $4,166,000 after buying an additional 5,945 shares in the last quarter.

Insmed Trading Down 0.5%

NASDAQ:INSM opened at $204.00 on Friday. The stock has a market cap of $43.51 billion, a price-to-earnings ratio of -32.96 and a beta of 1.01. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average price is $180.50 and its 200-day moving average price is $134.48. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The firm had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter in the previous year, the firm earned ($1.27) earnings per share. Insmed’s revenue was up 52.4% on a year-over-year basis. On average, equities research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Leo Lee sold 75,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $195.90, for a total transaction of $14,692,500.00. Following the sale, the director directly owned 54,677 shares of the company’s stock, valued at $10,711,224.30. This trade represents a 57.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Elizabeth M. Anderson sold 10,000 shares of Insmed stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $195.87, for a total value of $1,958,700.00. Following the completion of the sale, the director owned 63,729 shares of the company’s stock, valued at $12,482,599.23. The trade was a 13.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 233,650 shares of company stock valued at $41,063,785. Corporate insiders own 3.00% of the company’s stock.

Wall Street Analyst Weigh In

INSM has been the topic of a number of research analyst reports. The Goldman Sachs Group upped their target price on Insmed from $196.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Jefferies Financial Group lifted their price target on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, August 13th. Rothschild Redb upgraded Insmed to a “strong-buy” rating in a report on Thursday. Stifel Nicolaus raised their price objective on Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. Finally, Redburn Partners set a $263.00 target price on shares of Insmed in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $187.89.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.